DK3417074T3 - Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro - Google Patents

Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro Download PDF

Info

Publication number
DK3417074T3
DK3417074T3 DK17713238.8T DK17713238T DK3417074T3 DK 3417074 T3 DK3417074 T3 DK 3417074T3 DK 17713238 T DK17713238 T DK 17713238T DK 3417074 T3 DK3417074 T3 DK 3417074T3
Authority
DK
Denmark
Prior art keywords
vitro
arrays
agents
analytical methods
sensitizing effect
Prior art date
Application number
DK17713238.8T
Other languages
English (en)
Inventor
Carl A K Borrebaeck
Henrik Johansson
Ann-Sofie Albrekt
Kathrin Stephanie Zeller
Andy Andreas Sebastian Forreryd
Aakash Chawade
Tim Carl Sewe Lindberg
Malin Marie Lindstedt
Original Assignee
Senzagen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700138.9A external-priority patent/GB201700138D0/en
Application filed by Senzagen Ab filed Critical Senzagen Ab
Application granted granted Critical
Publication of DK3417074T3 publication Critical patent/DK3417074T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/763Herpes virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/148Screening for cosmetic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK17713238.8T 2016-03-23 2017-03-22 Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro DK3417074T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016056465 2016-03-23
GBGB1700138.9A GB201700138D0 (en) 2017-01-05 2017-01-05 Analytical methods and arrays for use in the same
PCT/EP2017/056878 WO2017162773A1 (en) 2016-03-23 2017-03-22 Analytical methods and arrays for use in the same

Publications (1)

Publication Number Publication Date
DK3417074T3 true DK3417074T3 (da) 2019-09-16

Family

ID=58410306

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17713238.8T DK3417074T3 (da) 2016-03-23 2017-03-22 Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro
DK19168388.7T DK3536805T3 (en) 2016-03-23 2017-03-22 Analytical methods and arrays for use in the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19168388.7T DK3536805T3 (en) 2016-03-23 2017-03-22 Analytical methods and arrays for use in the same

Country Status (12)

Country Link
EP (2) EP3536805B1 (da)
JP (2) JP7023857B2 (da)
KR (1) KR102402479B1 (da)
CN (1) CN108884493B (da)
AU (1) AU2017238455B2 (da)
BR (1) BR112018069279A2 (da)
CA (1) CA3017270A1 (da)
DK (2) DK3417074T3 (da)
ES (2) ES2745580T3 (da)
IL (1) IL261835B2 (da)
TW (1) TW201805430A (da)
WO (1) WO2017162773A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3417074T3 (da) * 2016-03-23 2019-09-16 Senzagen Ab Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro
GB201715445D0 (en) 2017-09-25 2017-11-08 Senzagen Ab Novel cell line and uses thereof
JP6722845B2 (ja) 2017-10-03 2020-07-15 株式会社国際電気通信基礎技術研究所 判別装置、うつ症状の判別方法、うつ症状のレベルの判定方法、うつ病患者の層別化方法、うつ症状の治療効果の判定方法及び脳活動訓練装置
CN110794047A (zh) * 2019-09-30 2020-02-14 广州市华代生物科技有限公司 一种复杂受试物对皮肤致敏性的预测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3169789D1 (en) 1980-05-02 1985-05-15 Edward P Davis Leg aid device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
EP1905843A1 (en) * 2006-09-29 2008-04-02 Vlaamse Instelling voor Technologisch Onderzoek Method for determining the allergic potential of a compound
JP5442185B2 (ja) * 2007-04-24 2014-03-12 日本メナード化粧品株式会社 感作性物質評価方法
US20090305276A1 (en) * 2008-06-04 2009-12-10 Mckim James M Method for Predicting Skin Sensitizing Activity of Compounds
GB201018014D0 (en) * 2010-10-26 2010-12-08 Senzagen Ab Analytical methods and arrays for use in the same
US20140213466A1 (en) * 2010-11-19 2014-07-31 Rutgers, The State University Of New Jersey High-throughput assessment method for contact hypersensitivity
GB201110371D0 (en) * 2011-06-17 2011-08-03 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
GB201207297D0 (en) * 2012-04-26 2012-06-06 Senzagen Ab Analytical methods and arrays for use in the same
EP2835640A1 (en) * 2013-08-06 2015-02-11 Academisch Ziekenhuis Leiden HODN Leids Universitair Medisch Centrum Method for predicting the skin sensitizing activity of a compound.
JP6378529B2 (ja) 2014-04-28 2018-08-22 国立大学法人 鹿児島大学 遺伝性疾患の検出方法
DK3417074T3 (da) 2016-03-23 2019-09-16 Senzagen Ab Analytiske fremgangsmåder og arrays til bestemmelse af den hudsensibiliserende virkning af midler in vitro

Also Published As

Publication number Publication date
CN108884493B (zh) 2022-07-19
EP3417074B1 (en) 2019-06-12
EP3536805B1 (en) 2022-11-02
JP2019516950A (ja) 2019-06-20
JP7261852B2 (ja) 2023-04-20
BR112018069279A2 (pt) 2019-01-22
AU2017238455B2 (en) 2023-01-19
JP2022009855A (ja) 2022-01-14
WO2017162773A1 (en) 2017-09-28
IL261835B (en) 2022-11-01
EP3417074A1 (en) 2018-12-26
DK3536805T3 (en) 2022-11-14
CA3017270A1 (en) 2017-09-28
CN108884493A (zh) 2018-11-23
AU2017238455A1 (en) 2018-10-04
JP7023857B2 (ja) 2022-02-22
KR102402479B1 (ko) 2022-05-25
EP3536805A2 (en) 2019-09-11
TW201805430A (zh) 2018-02-16
EP3536805A3 (en) 2019-09-25
ES2934349T3 (es) 2023-02-21
IL261835A (en) 2018-10-31
IL261835B2 (en) 2023-03-01
KR20180128422A (ko) 2018-12-03
ES2745580T3 (es) 2020-03-02

Similar Documents

Publication Publication Date Title
DK3515478T3 (da) Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3333192T3 (da) Antistof imod glypican-3 og anvendelse deraf
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3707159T5 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3464282T3 (da) Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
CL2016002416A1 (es) Composiciones estables de yodo no en complejo y métodos de uso
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3380522T3 (da) Antistofmolekyler til april og anvendelser deraf
DK3083689T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK2953969T3 (da) Anti-IL-17A-antistoffer og deres anvendelse til behandling af autoimmune og inflammatoriske forstyrrelser
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme